Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate

Imatinib mesylate (IM) is a small molecule inhibitor of protein tyrosine kinases. In addition to its direct effect on malignant cells, it has been suggested IM may activate of natural killer (NK) cells, hence exerting immunomodulatory functions. In preclinical settings, improved antitumor responses...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Pautier, Patricia, Locher, Clara, Robert, Caroline, Deroussent, Alain, Flament, Caroline, Le Cesne, Axel, Rey, Annie, Bahleda, Ratislav, Ribrag, Vincent, Soria, Jean-Charles, Vassal, Gilles, Eggermont, Alexander, Zitvogel, Laurence, Chaput, Nathalie, Paci, Angelo
Format: Artigo
Sprog:Inglês
Udgivet: Landes Bioscience 2013
Fag:
Research Paper
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3601177/
https://ncbi.nlm.nih.gov/pubmed/23525192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.23079
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker